The estimated Net Worth of Jane Henderson is at least $1.31 Milione dollars as of 16 June 2023. Ms. Henderson owns over 40,000 units of Akero Therapeutics Inc stock worth over $1,024,800 and over the last 8 years she sold AKRO stock worth over $0. In addition, she makes $282,568 as Non-Executive Independent Director at Akero Therapeutics Inc.
Jane has made over 5 trades of the Akero Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 40,000 units of AKRO stock worth $280,400 on 16 June 2023.
The largest trade she's ever made was exercising 40,000 units of Akero Therapeutics Inc stock on 16 June 2023 worth over $280,400. On average, Jane trades about 4,420 units every 77 days since 2016. As of 16 June 2023 she still owns at least 40,000 units of Akero Therapeutics Inc stock.
You can see the complete history of Ms. Henderson stock trades at the bottom of the page.
Jane Pritchett Henderson serves as Non-Executive Independent Director of the Company. Ms. Henderson has served as a member of our board of directors since April 2019. Ms. Henderson currently serves as the Chief Financial Officer of Turnstone Biologics, Inc., a viral immuno-oncology company, a position she has held since June 2018. Prior to joining Turnstone Biologics, Ms. Henderson served as Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, Inc., a gene therapy company, since January 2017. She also served as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., an oncology biopharmaceutical company, from February 2013 until November 2016, when Kolltan Pharmaceuticals was acquired by Celldex Therapeutics, Inc. Prior to Kolltan Pharmaceuticals, Ms. Henderson served in various financial and business development executive roles at biopharmaceutical companies after spending almost 20 years in health care investment banking. During the past five years, Ms. Henderson has served on the board of directors of Sesen Bio Inc., a biopharmaceutical company, and IVERIC Bio, Inc., a biopharmaceutical company. Ms. Henderson received a B.S. in psychology from Duke University.
As the Non-Executive Independent Director of Akero Therapeutics Inc, the total compensation of Jane Henderson at Akero Therapeutics Inc is $282,568. There are 13 executives at Akero Therapeutics Inc getting paid more, with Andrew Cheng having the highest compensation of $5,431,810.
Jane's mailing address filed with the SEC is 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at Akero Therapeutics Inc have traded over $146,260,704 worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth $104,250,550 . The most active insiders traders include Group, Llc Green Jeremy Red..., Trust Blue Horizon Enterpri... e G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,642,344. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth $133,600.
akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
Akero Therapeutics Inc executives and other stock owners filed with the SEC include: